Reta research: A1C improvement, Knee Osteoarthritis, Fatty Liver Disease, Lipids, Kidneys, Sleep Apnea, and more

[oldrunnerguy]

The latest Phase 3 data (released in December 2025 and March 2026 ) shows that retatrutide is moving far beyond just being a "weight loss drug." Because it targets three different hormones—GLP-1, GIP, and Glucagon—it acts as a systemic metabolic "clean-up" tool.

Here is the breakdown of the most recent research on retatrutide’s non-weight-related uses: GLP1's are definitely having a moment! Showing great efficacy for those wanting to lose weight, and so much more.

1. In results published on March 19, 2026 , retatrutide showed massive efficacy in glycemic control:​[archived internal link]

A1C Reduction: Participants saw an average A1C reduction of 1.7% to 2.0% over 40 weeks [1.2].

Glycemic Reach: Many participants reached "near-normal" glucose levels, suggesting it may be more potent for blood sugar control than current dual-agonists.

2. One of the most surprising results from the December 2025 data was the drug’s impact on chronic pain:​[archived internal link]

Pain Reduction: Participants saw a 75.8% reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores [2.2].

Mechanical vs. Inflammatory: While some of this is due to taking weight off the joints, the drug also significantly lowered hsCRP (a marker of systemic inflammation), suggesting a direct anti-inflammatory effect on the joint tissue itself.

3. Retatrutide is currently the "front runner" for resolving Metabolic Dysfunction-Associated Steatohepatitis (MASH):​[archived internal link]

Steatosis Resolution: Phase 2 data showed that 85-90% of participants achieved "normalization" of liver fat (liver fat <5%) within 48 weeks [3.2].

Phase 3 Ongoing: The SYNERGY-Outcomes trial is currently evaluating whether retatrutide can prevent "major adverse liver outcomes" (like cirrhosis) in high-risk patients [3.1].

4. Cardiovascular & Kidney Protection

The TRIUMPH-Outcomes trial (updated in March 2026 ) is specifically studying retatrutide’s ability to prevent heart attacks and kidney failure [5.3]:

Blood Pressure: Recent data shows an average systolic blood pressure (SBP) drop of 14.0 mmHg [1.1].

Lipid Clearing: It significantly lowers triglycerides and non-HDL cholesterol , potentially offering "primary prevention" for heart disease.

5. Sleep Apnea & Chronic Back Pain​[archived internal link]
The TRIUMPH-1 trial (expected completion mid-2026) is evaluating:

Obstructive Sleep Apnea (OSA): Measuring the reduction in the Apnea-Hypopnea Index (AHI) [4.1].

Chronic Low Back Pain: Looking at how systemic inflammation reduction and weight loss combine to relieve spinal pressure.

Why it works for so many things: The "Triple Agonist" Effect​[archived internal link]
Retatrutide’s unique ability to hit Glucagon receptors in addition to GLP-1 and GIP is the "secret sauce" for these non-weight benefits.

GLP-1: Reduces appetite and calms the immune system.

GIP: Improves how the body clears lipids and reduces bone resorption.

Glucagon: Increases energy expenditure and promotes liver fat oxidation (burning fat directly in the liver).

During my working life, I was a pharmacist for more than 43 years. Way the hell back in the early 90's I remember reading about an exciting new class of drugs showing tremendous potential for a variety of afflictions, but the focus was about diabetics and weight loss. I find this class of drugs fascinating, and their potential to improve health outcomes for mllions and millions of people. 30+ years later and I'm totally nerding out on everything GLP1-related. Reta is incredible, and I'm excited to learn about current research on the quadruple agonist drug NA-931 Bioglutide. (Look it up).

 

[staffn1]

How does all of that compare to trizepatide?

 

[JFinHK]

Yes, loving Reta and hoping for easy access for all when it finally comes out officially!

 

[CMA Pooky]

The latest Phase 3 data (released in December 2025 and March 2026 ) shows that retatrutide is moving far beyond just being a "weight loss drug." Because it targets three different hormones—GLP-1, GIP, and Glucagon—it acts as a systemic metabolic "clean-up" tool.

Here is the breakdown of the most recent research on retatrutide’s non-weight-related uses: GLP1's are definitely having a moment! Showing great efficacy for those wanting to lose weight, and so much more.

1. In results published on March 19, 2026 , retatrutide showed massive efficacy in glycemic control:​

A1C Reduction: Participants saw an average A1C reduction of 1.7% to 2.0% over 40 weeks [1.2].

Glycemic Reach: Many participants reached "near-normal" glucose levels, suggesting it may be more potent for blood sugar control than current dual-agonists.

2. One of the most surprising results from the December 2025 data was the drug’s impact on chronic pain:​

Pain Reduction: Participants saw a 75.8% reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores [2.2].

Mechanical vs. Inflammatory: While some of this is due to taking weight off the joints, the drug also significantly lowered hsCRP (a marker of systemic inflammation), suggesting a direct anti-inflammatory effect on the joint tissue itself.

3. Retatrutide is currently the "front runner" for resolving Metabolic Dysfunction-Associated Steatohepatitis (MASH):​

Steatosis Resolution: Phase 2 data showed that 85-90% of participants achieved "normalization" of liver fat (liver fat

 

[biobob]

Everything I hear about Reta is amazing. Thanks for sharing. I am 4 weeks in and feeling good.

 

[latviantower]

… and I'm excited to learn about current research on the quadruple agonist drug NA-931 Bioglutide. (Look it up).

Don’t waste your time. Bioglutide is a fraud. (Look it up.)

Eloralintide, on the other hand, piques my interest.

​[archived internal link]

 

[oldrunnerguy]

I forgot to add this part:

Here is a summary of the latest research regarding retatrutide and mental health benefits as of March 2026.

1. The "Happiness Signal" in Phase 3​[archived internal link]
In the TRIUMPH-4 and TRANSCEND results released over the last few months, researchers included "exit interviews" and Quality of Life (QoL) metrics that went beyond the scale.

Emotional Well-being: In a qualitative study of Phase 2 and 3 participants (published late 2025), patients didn't just report "less hunger"—they reported feeling "happier," "more self-confident," and possessing a sense of "emotional regulation" they hadn't felt in years [5.1].

Reduction in "Food Noise": This is the most cited mental benefit. By quieting the constant internal negotiation about food, patients report a "mental clarity" and a reduction in the cognitive load that previously fueled anxiety and binge-eating cycles [1.1].

2. The Landmark "42% Reduction" Study (March 2026)​[archived internal link]
While we wait for the final peer-reviewed "mental health sub-study" for retatrutide, a massive study published in The Lancet Psychiatry (March 19, 2026) analyzed over 95,000 people on GLP-1 class drugs.

Psychiatric Stability: The study found that users were 42% less likely to experience a worsening of mental illness (hospitalization or sick leave) compared to periods when they weren't on the medication [4.1, 4.4].

Broad Spectrum: This benefit applied to depression, anxiety, and specifically substance use disorders (47% reduction). Since retatrutide is a "triple agonist," researchers believe it may be even more potent in this regard due to the way it interacts with the brain's reward centers.

3. The Mechanism: Neuroinflammation​[archived internal link]
Here is how retatrutide treats the brain. It’s not just about "feeling good because you look good."

Anti-Inflammatory Action: Retatrutide (and its cousins) cross the blood-brain barrier and reduce neuroinflammation —the activation of glial cells that is a known driver of clinical depression and anhedonia [5.2].

Dopamine Tuning: By modulating the GLP-1 and GIP receptors in the ventral tegmental area (the reward center), these drugs "level out" the dopamine spikes that drive impulsive behaviors (food, alcohol, or even "doom-scrolling") [4.2].

4. The 2026 FDA Safety Correction​[archived internal link]
Crucially for your "correct way" of doing things, the FDA announced in January 2026 that it is requesting the removal of suicidal ideation warnings from these medications [1.1]. After analyzing data from over 100,000 patients, they found no increased risk of serious psychiatric side effects, essentially clearing the "dark cloud" that had hovered over the class for years.

 

[lessthanhalf]

Unfortunately there are significant scientific inaccuracies in that summary, the thing I immediately noticed was the Blood brain barrier bit, that retatrutide and other GLP's cross the BBB. Basically they are too large to do this, they definitely affect the brain but mainly through areas less protected by the BBB, and via secondary effects through vagal nerve responses, and due to alterations in hormonal signalling. I think it would be very interesting to see if any small molecule multiagonists do get through the BBB, and what effects that then has on the brain given how significant the effects are when it only accesses small parts of the brain, especially in terms of preventing cognitive impairment with aging.

Most of the other issues are more that effects are overstated and presented as far more certain than the current science supports . This applies to effects on MASH, pain, psychiatric issues. While the effects on lipids and blood pressure are good, and it probably will eventually be shown to be protective against cardiovascular disease and renal function, this has not yet been shown for reta, but has for tirzepatide and semaglutide. While reta is effective at reducing liver fat, it has not yet been shown to have an effect on fibrosis, and reversing this or slowing it down is the important issue. Again it may well be shown to do this in the future but has not yet been done.

I think this is the classic AI wants to tell a coherent story problem, and is overstating effects and getting some facts wrong. It can be reduced by using research /scholar mode or by prompting .